cancer

Incyclix Bio’s CDK2 inhibitor, INX-315, has received FDA Fast Track designation for treating CCNE1-amplified, platinum-resistant/refractory ovarian cancer. This designation...

Harbinger Health presented new research at the American Association for Cancer Research (AACR) Annual Meeting showcasing advancements in their...

The Oncology Institute (TOI) is expanding its partnership with Helios Clinical Research to bring clinical trials to more community...

HUTCHMED has completed enrollment for the registration phase of its Phase II savolitinib trial in gastric cancer patients with...

Compass Therapeutics has initiated the first patient dosing in an Investigator Sponsored Trial (IST) at MD Anderson Cancer Center....

Can-Fite BioPharma announced that major U.S. medical centers are requesting FDA compassionate use approval for Namodenoson, its pancreatic cancer...

BriaCell Therapeutics Corp. announced positive survival data from its Phase 2 study of Bria-IMT™ combined with checkpoint inhibitors in...

Cardiff Oncology has completed patient enrollment in its Phase 2 CRDF-004 trial. The trial is evaluating onvansertib combined with...

Oryzon Genomics has initiated a Phase I/II trial evaluating iadademstat, an LSD1 inhibitor, combined with immune checkpoint inhibitors (atezolizumab...

Sonnet BioTherapeutics announced positive safety results for SON-1010, an IL-12 based immunotherapy, combined with atezolizumab in a Phase 1b/2a...